STOCK TITAN

[S-8 POS] Enzo Biochem, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Enzo Biochem, Inc. (ENZ) filed an S-8 post-effective amendment that catalogs prior employee equity registration statements covering multiple stock plans. The filing lists historic registrations dating from 1983 through 2021, including specific registrations for 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000 and a 960,000-share registration tied to inducement awards granted on November 8, 2021. The document is an administrative update to available shares for employee benefit and incentive plans.

Enzo Biochem, Inc. (ENZ) ha depositato un emendamento post-effettivo del modulo S-8 che elenca le precedenti registrazioni azionarie destinate ai dipendenti, riferite a vari piani di azionariato. Il documento include registrazioni storiche datate dal 1983 al 2021, comprese registrazioni specifiche per 988.951, 950.000, 1.000.000, 2.000.000, 3.000.000, 4.000.000 e una registrazione di 960.000 azioni legata a premi di incentivazione concessi il 8 novembre 2021. Il documento è un aggiornamento amministrativo relativo alle azioni disponibili per i piani di benefici e incentivi per i dipendenti.

Enzo Biochem, Inc. (ENZ) presentó una enmienda posterior a la vigencia del Formulario S-8 que detalla las declaraciones de registro de acciones previas para empleados, correspondientes a diversos planes de acciones. El documento enumera registros históricos que van desde 1983 hasta 2021, incluyendo registros específicos para 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000 y un registro de 960,000 acciones vinculado a premios por inducción otorgados el 8 de noviembre de 2021. El documento es una actualización administrativa de las acciones disponibles para planes de beneficios e incentivos para empleados.

Enzo Biochem, Inc. (ENZ) 은 직원 보상 및 인센티브 계획용으로 다수의 주식 등록을 포함하는 S-8 포스트 이펙티브 수정안을 제출했습니다. 이 문서는 1983에서 2021까지의 과거 등록을 나열하며, 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000960,000 주의 유인 보상으로 발급된 2021년 11월 8일에 연결된 등록을 포함합니다. 이 문서는 직원 혜택 및 유인 제도에 대해 이용 가능한 주식의 관리상 업데이트입니다.

Enzo Biochem, Inc. (ENZ) a déposé un amendement post-entrée en vigueur S-8 qui récapitule les déclarations d’enregistrement d’actions antérieures destinées aux employés couvrant plusieurs plans d’actions. Le dépôt répertorie des enregistrements historiques allant de 1983 à 2021, y compris des enregistrements spécifiques pour 988 951, 950 000, 1 000 000, 2 000 000, 3 000 000, 4 000 000 et un enregistrement de 960 000 actions lié à des récompenses d’induction accordées le 8 novembre 2021. Le document est une mise à jour administrative des actions disponibles pour les plans d’avantages et d’incitations pour les employés.

Enzo Biochem, Inc. (ENZ) hat eine S-8-Nachgenehmigung (Post-Effective Amendment) eingereicht, die frühere Aktien-Registrierungen der Mitarbeiter für mehrere Aktienpläne auflistet. Die Einreichung führt historische Registrierungen auf von 1983 bis 2021, einschließlich spezifischer Registrierungen für 988.951, 950.000, 1.000.000, 2.000.000, 3.000.000, 4.000.000 und eine 960.000-Aktien-Registrierung im Zusammenhang mit Inducement-Boni, die am 8. November 2021 gewährt wurden. Das Dokument ist eine administrative Aktualisierung der verfügbaren Aktien für Mitarbeiterbenefit- und Anreizpläne.

Enzo Biochem, Inc. (ENZ) قدمت تعديلًا لاحقًا لتفعيل نموذج S-8 يوثق بيانات تسجيل الأسهم السابقة الخاصة بالموظفين وتغطي عدة خطط أسهم. يسرد الملف تسجيلات تاريخية تمتد من 1983 حتى 2021، بما في ذلك تسجيلات محددة لـ 988,951، 950,000، 1,000,000، 2,000,000، 3,000,000، 4,000,000 و تسجيل يضم 960,000 سهماً مرتبطاً بمنح حوافز في تاريخ 8 نوفمبر 2021. المستند هو تحديث إداري لعدد الأسهم المتاحة لخطط العوائد والمحفّزات للموظفين.

Positive
  • None.
Negative
  • None.

Enzo Biochem, Inc. (ENZ) ha depositato un emendamento post-effettivo del modulo S-8 che elenca le precedenti registrazioni azionarie destinate ai dipendenti, riferite a vari piani di azionariato. Il documento include registrazioni storiche datate dal 1983 al 2021, comprese registrazioni specifiche per 988.951, 950.000, 1.000.000, 2.000.000, 3.000.000, 4.000.000 e una registrazione di 960.000 azioni legata a premi di incentivazione concessi il 8 novembre 2021. Il documento è un aggiornamento amministrativo relativo alle azioni disponibili per i piani di benefici e incentivi per i dipendenti.

Enzo Biochem, Inc. (ENZ) presentó una enmienda posterior a la vigencia del Formulario S-8 que detalla las declaraciones de registro de acciones previas para empleados, correspondientes a diversos planes de acciones. El documento enumera registros históricos que van desde 1983 hasta 2021, incluyendo registros específicos para 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000 y un registro de 960,000 acciones vinculado a premios por inducción otorgados el 8 de noviembre de 2021. El documento es una actualización administrativa de las acciones disponibles para planes de beneficios e incentivos para empleados.

Enzo Biochem, Inc. (ENZ) 은 직원 보상 및 인센티브 계획용으로 다수의 주식 등록을 포함하는 S-8 포스트 이펙티브 수정안을 제출했습니다. 이 문서는 1983에서 2021까지의 과거 등록을 나열하며, 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000960,000 주의 유인 보상으로 발급된 2021년 11월 8일에 연결된 등록을 포함합니다. 이 문서는 직원 혜택 및 유인 제도에 대해 이용 가능한 주식의 관리상 업데이트입니다.

Enzo Biochem, Inc. (ENZ) a déposé un amendement post-entrée en vigueur S-8 qui récapitule les déclarations d’enregistrement d’actions antérieures destinées aux employés couvrant plusieurs plans d’actions. Le dépôt répertorie des enregistrements historiques allant de 1983 à 2021, y compris des enregistrements spécifiques pour 988 951, 950 000, 1 000 000, 2 000 000, 3 000 000, 4 000 000 et un enregistrement de 960 000 actions lié à des récompenses d’induction accordées le 8 novembre 2021. Le document est une mise à jour administrative des actions disponibles pour les plans d’avantages et d’incitations pour les employés.

Enzo Biochem, Inc. (ENZ) hat eine S-8-Nachgenehmigung (Post-Effective Amendment) eingereicht, die frühere Aktien-Registrierungen der Mitarbeiter für mehrere Aktienpläne auflistet. Die Einreichung führt historische Registrierungen auf von 1983 bis 2021, einschließlich spezifischer Registrierungen für 988.951, 950.000, 1.000.000, 2.000.000, 3.000.000, 4.000.000 und eine 960.000-Aktien-Registrierung im Zusammenhang mit Inducement-Boni, die am 8. November 2021 gewährt wurden. Das Dokument ist eine administrative Aktualisierung der verfügbaren Aktien für Mitarbeiterbenefit- und Anreizpläne.

Enzo Biochem, Inc. (ENZ) قدمت تعديلًا لاحقًا لتفعيل نموذج S-8 يوثق بيانات تسجيل الأسهم السابقة الخاصة بالموظفين وتغطي عدة خطط أسهم. يسرد الملف تسجيلات تاريخية تمتد من 1983 حتى 2021، بما في ذلك تسجيلات محددة لـ 988,951، 950,000، 1,000,000، 2,000,000، 3,000,000، 4,000,000 و تسجيل يضم 960,000 سهماً مرتبطاً بمنح حوافز في تاريخ 8 نوفمبر 2021. المستند هو تحديث إداري لعدد الأسهم المتاحة لخطط العوائد والمحفّزات للموظفين.

Enzo Biochem, Inc. (ENZ) 已提交 S-8 生效后修订,列出覆盖多项员工股票计划的先前注册声明。该文件列出自 19832021 的历史注册记录,其中包括特定的 988,951950,0001,000,0002,000,0003,000,0004,000,000 以及与在 2021年11月8日 授予的诱导性奖励相关联的 960,000 股注册。该文件是对员工福利与激励计划可用股份的行政更新。

As filed with the Securities and Exchange Commission on August 20, 2025

No. 33-88826

No. 333-87153

No. 333-89308

No. 333-123712

No. 333-172127

No. 333-197028

No. 333-226799

No. 333-236958

No. 333-252159

No. 333-260894

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826

 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-87153

Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 333-123712

Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-172127

Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-197028

Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-226799

Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-236958

Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-252159

Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-260894

 

UNDER

THE SECURITIES ACT OF 1933 

 

 

 

ENZO BIOCHEM, INC.

(Exact name of registrant as specified in its charter) 

 

 

 

New York   13-2866202

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

21 Executive Blvd.
Farmingdale, New York
  11735
(Address of Principal Executive Offices)   (Zip Code)

 

 

 

Enzo Biochem, Inc. 1999 Stock Option Plan

Enzo Biochem, Inc. Salary Reduction Profit Sharing Plan

Enzo Biochem, Inc. Amended and Restated 2011 Incentive Plan

(as amended and restated effective as of October 7, 2020)

Inducement Sign-On Restricted Stock Unit Grant Notice and Agreement

Inducement Sign-On Option Grant Notice and Agreement

(Full title of the plans) 

 

 

 

Patricia Eckert

Chief Financial Officer

21 Executive Blvd.

Farmingdale, New York 11735

(631) 755-5500

(Name, address and telephone number of agent for service)

 

 

 

Copy To:

 

Adam Finerman

Baker & Hostetler LLP

45 Rockefeller Plaza

New York, NY 10111

(212) 589-4233

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
       
Non-accelerated filer Smaller reporting company
       
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

 

 

EXPLANATORY NOTE

 

These Post-Effective Amendments (these “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by Enzo Biochem, Inc. (the “Company”):

 

Registration Statement filed with the SEC on December 28, 1983, and any amendments thereto, pertaining to the registration of a number of shares of common stock, par value $0.01 (“Common Stock”) pursuant to an employee benefit plan.

 

Registration Statement filed with the SEC on January 28, 1992, and any amendments thereto, pertaining to the registration of a number of shares of Common Stock pursuant to an employee benefit plan.

 

Registration Statement filed with the SEC on February 18, 1994, pertaining to the registration of a number of shares of Common Stock pursuant to an employee benefit plan.

 

Registration Statement No. 33-88826 filed with the SEC on January 27, 1995, and Amendment No. 1 to the Registration Statement filed with the SEC on January 27, 2000, pertaining to the registration of an aggregate of 988,951 shares of Common Stock pursuant to the 1994 Plan;

 

Registration Statement No. 333-87153 filed with the SEC on September 15, 1999, pertaining to the registration of an aggregate of 950,000 shares of Common Stock pursuant to the 1999 Stock Option Plan (the “1999 Plan”);

 

Registration Statement No. 333-89308 filed with the SEC on May 29, 2002, pertaining to the registration of 1,000,000 shares of Common Stock pursuant to the 1999 Plan;

 

Registration Statement No. 333-123712 filed with the SEC on March 31, 2005, and Amendment No. 1 to the Registration Statement field with the SEC on April 21, 2006, pertaining to the registration of an aggregate of 2,000,000 shares of Common Stock pursuant to the 1994 Plan, the 1999 Plan and the 2005 Equity Compensation Incentive Plan;

 

Registration Statement No. 333-172127 filed with the SEC on February 9, 2011, pertaining to the registration of 3,000,000 shares of Common Stock pursuant to the 2011 Incentive Plan, as amended and restated (the “2011 Incentive Plan”);

 

Registration Statement No. 333-197028 filed with the SEC on June 25, 2014, pertaining to the registration of 1,000,000 shares of Common Stock pursuant to the Salary Reduction Profit Sharing Plan (the “Profit Sharing Plan);

 

Registration Statement No. 333-226799 filed with the SEC on August 13, 2018, pertaining to the registration of 2,000,000 shares of Common Stock pursuant to the 2011 Plan;

 

Registration Statement No. 333-236958 filed with the SEC on March 6, 2020, pertaining to the registration of 1,000,000 shares of Common Stock pursuant to the Profit Sharing Plan;

 

Registration Statement No. 333-252159 filed with the SEC on January 15, 2021, pertaining to the registration of 4,000,000 shares of Common Stock pursuant to the 2011 Plan; and

 

Registration Statement No. 333-260894, filed with the SEC on November 9, 2021, pertaining to the registration of an aggregate of 960,000 shares consisting of: (i) 260,000 shares of Common Stock issuable pursuant to an inducement restricted stock unit award granted on November 8, 2021 and (ii) 700,000 shares of Common Stock issuable pursuant to an inducement stock option award granted on November 8, 2021.

 

On June 23, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bethpage Parent, Inc., a Delaware corporation (“Parent”) and Bethpage Merger Sub, Inc., a New York corporation and wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on August 20, 2025, Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

 

In connection with the Merger, the offerings of securities pursuant to the Registration Statements have been terminated. In accordance with the undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered pursuant to the Registration Statements which remain unsold at the termination of the offerings, the Company hereby terminates the effectiveness of each Registration Statement and removes from registration all Shares registered under the Registration Statements that remain unsold as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Company pursuant to the Registration Statements.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Farmingdale, State of New York, on August 20, 2025.

 

ENZO BIOCHEM, INC.  
     
By: /s/ Patricia Eckert  
Name: Patricia Eckert  
Title: Chief Financial Officer  

 

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

 

 

 

 

FAQ

What does the ENZ S-8 post-effective amendment do?

The filing catalogs prior employee-plan registration statements and confirms the shares registered for various equity compensation plans dating from 1983 through 2021.

How many shares were registered under the 2021 registration for the 2011 Plan?

The 2021 registration (No. 333-252159) pertains to 4,000,000 shares issued under the 2011 Incentive Plan as disclosed in the filing.

What were the inducement awards disclosed in the filing?

Registration No. 333-260894 filed on November 9, 2021 covered an aggregate of 960,000 shares consisting of 260,000 inducement restricted stock units and 700,000 inducement stock options granted on November 8, 2021.

Does the filing report any new financing, acquisitions, or earnings?

No. The document only lists historical registration statements for employee benefit and equity incentive plans and does not include financing, transaction, or earnings data.

Which historical registration sizes are specifically listed in the filing?

The filing lists specific registrations including 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000, and 960,000 shares tied to various plans and dates.
Enzo Biochem Inc

NYSE:ENZ

ENZ Rankings

ENZ Latest News

ENZ Latest SEC Filings

ENZ Stock Data

31.65M
41.04M
Testing Laboratories
Services-medical Laboratories
Link
US
FARMINGDALE